We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: DNA methylation
MedXY News
EnglishTag

DNA methylation

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligenceclinical trialstype 1 diabetesHypertensiononcologyCardiologypublic healthdiabetesMortalitycardiovascular diseaseAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Unraveling Abdominal Aortic Aneurysm: Epigenetic Links to Inflammation and Lipid Metabolism
CardiologyAbdominal Aortic AneurysmChuyển hóa mỡ máu

Unraveling Abdominal Aortic Aneurysm: Epigenetic Links to Inflammation and Lipid Metabolism

By MedXY|Oct 3, 2026

An epigenome-wide study reveals that DNA methylation markers linked to inflammatory pathways and blood lipid traits play a causal role in abdominal aortic aneurysm development, offering potential for improved risk prediction and therapeutic

Enhancing Prognostic Accuracy in Acute Myeloid Leukemia through DNA Methylation Signatures
Hematology-OncologyDNA methylationprognostic markers
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Enhancing Prognostic Accuracy in Acute Myeloid Leukemia through DNA Methylation Signatures

By MedXY|Aug 28, 2026

DNA methylation profiling in AML patients reveals epigenetic subtypes that mirror genetic mutations, improving risk stratification and outcome prediction beyond standard genetic markers.

Blood-Based DNA Methylation Models May Improve Cardiovascular Risk Prediction in Type 2 Diabetes
CardiologyDNA methylationcardiovascular risk

Blood-Based DNA Methylation Models May Improve Cardiovascular Risk Prediction in Type 2 Diabetes

By MedXY|Jul 25, 2026

A study of 305 individuals with type 2 diabetes found that blood-based DNA methylation models predicted 5-year major adverse cardiovascular events with high accuracy, suggesting potential for improved risk stratification.

Enhancing Triage of Non-16/18 High-Risk HPV Cervical Lesions Using FAM19A4, SOX1, and PAX1 Methylation Testing
newstriageHPV

Enhancing Triage of Non-16/18 High-Risk HPV Cervical Lesions Using FAM19A4, SOX1, and PAX1 Methylation Testing

By MedXY|Aug 18, 2026

FAM19A4, SOX1, and PAX1 methylation assays demonstrate high diagnostic accuracy for identifying CIN3+ among non-16/18 hrHPV-positive women, outperforming cytology and reducing unnecessary colposcopies.

Blood DNA Methylation Maps Atherosclerosis Across Vascular Beds: Strong Signals, but Mostly a Record of Cumulative Risk Exposure
CardiologyatherosclerosisDNA methylation

Blood DNA Methylation Maps Atherosclerosis Across Vascular Beds: Strong Signals, but Mostly a Record of Cumulative Risk Exposure

By MedXY|Jun 19, 2026

In 2 prospective cohorts, blood DNA methylation was associated with carotid, coronary, and peripheral atherosclerosis, but most signals overlapped with smoking and cardiometabolic risk factors rather than vessel-specific biology.

FET-rearranged Myoepithelial Tumors: Why Epigenetics Demands a Shift from Carcinoma to Sarcoma Classification
newsDNA methylationPrecision oncology

FET-rearranged Myoepithelial Tumors: Why Epigenetics Demands a Shift from Carcinoma to Sarcoma Classification

By MedXY|Jan 12, 2026

A landmark study reveals that FET-rearranged myoepithelial tumors are epigenetically distinct from PLAG1-rearranged salivary and adnexal variants, suggesting they are closer to sarcomas than carcinomas, with significant clinical implication

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings
GastroenterologybiologicsCrohn’s disease

Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings

By MedXY|Nov 9, 2025

An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models